Literature DB >> 9842983

Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration.

C Mircioiu1, A Perju, E Griu, G Calin, A Neagu, D Enachescu, D S Miron.   

Abstract

Progesterone was administered percutaneously to postmenopausal women in topical applications on the breast and chest areas in a hydrophilic (gel), lipophilic and an emulsion type base. Venous blood samples were taken 2, 4, 6, 24, 48 and 72 h following administration. The plasma levels were evaluated by radioimmunoassay. Time of maximum concentration (tmax) was, in all cases, in the neighborhood of 4 h. Mean peak plasma concentrations were: 1 ng/ml for the lipophilic, 1.24 ng/ml for the hydrophilic and 2.26 ng/ml for the emulsion type base. The areas under the curves (AUCs) were practically equivalent for the first two methods, but higher values were obtained for administration in the emulsion type base. The elimination was slow, with a half-time varying in the range of 3040 h for all three types of base, a value that was much higher than those obtained after administration of progesterone via vaginal suppositories. The AUCs were parallel with the peak plasma concentrations: almost 2-fold higher for emulsion than for the gel and lipophilic base. Fit for plasma levels using mono-, bi- and tricompartmental models furnished acceptable results only in the case of monocompartmental model, which raises a number of physiological and physico-chemical considerations. A 'pseudomonocompartmental' model was constructed to explain this 'anomaly'.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842983     DOI: 10.1007/BF03192300

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome.

Authors:  S Maddocks; P Hahn; F Moller; R L Reid
Journal:  Am J Obstet Gynecol       Date:  1986-03       Impact factor: 8.661

2.  Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone.

Authors:  S J Nillius; E D Johansson
Journal:  Am J Obstet Gynecol       Date:  1971-06-15       Impact factor: 8.661

3.  [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue].

Authors:  R Morville; F Dray; J Reynier; J Barrat
Journal:  J Gynecol Obstet Biol Reprod (Paris)       Date:  1982

4.  Increasing oral bioavailability of progesterone by formulation.

Authors:  F A Kincl; L A Ciaccio; G Benagiano
Journal:  J Steroid Biochem       Date:  1978-01       Impact factor: 4.292

5.  Progesterone-4-14C and its metabolites in the blood after intravenous injection into women.

Authors:  J H Thijssen; J Zander
Journal:  Acta Endocrinol (Copenh)       Date:  1966-04

6.  Percutaneous absorption of steroids: relative contributions of epidermal penetration and dermal clearance.

Authors:  O Siddiqui; M S Roberts; A E Polack
Journal:  J Pharmacokinet Biopharm       Date:  1989-08

7.  Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone.

Authors:  D F Archer; G E Fahy; A Viniegra-Sibal; F D Anderson; W Snipes; R G Foldesy
Journal:  Am J Obstet Gynecol       Date:  1995-08       Impact factor: 8.661

8.  Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration.

Authors:  C Mircioiu; A Perju; A Neagu; E Griu; G Calin; D S Miron
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.